## Clinical Research on Tubulin Inhibition and Anti-angiogenic Agents in TNBC

Edith A Perez, MD

### **Disclosures for Edith A Perez, MD**

## Paid Research to Mayo Clinic


Genentech BioOncology, GlaxoSmithKline, Roche Laboratories Inc, sanofi-aventis

### **Key Topics Discussed**

Anti-tubulin agents and TNBC: Taxanes and ixabepilone

Angiogenesis inhibitors and TNBC: Bevacizumab

## CALGB-40603: The Triple-Negative Neoadjuvant Trial (TNNT)



Courtesy of Clifford A Hudis.

Response to Neoadjuvant Therapy and Long-Term Survival in Patients with Triple-Negative Breast Cancer

Liedtke C et al. J Clin Oncol 2008;26(8):1275-81.

# pCR Rates to Neoadjuvant Chemotherapy as a Function of Triple-Negative Status

	pCR Rates			
Regimens	All Patients	TNBC	Non- TNBC	<i>p</i> -value
FAC/FEC/AC (n = 308)	8%	20%	5%	0.0001
TFAC/TFEC (n = 588)	19%	28%	17%	0.0072
Single-agent taxane (n = 58)	5%	12%	2%	0.82

Patients with TNBC have a higher incidence of pCR to taxane-based regimens

Liedtke C et al. J Clin Oncol 2008;26(8):1275-81.

Breast Cancer Molecular Profiles Predict Tumor Response of Neoadjuvant Doxorubicin and Paclitaxel, the I-SPY TRIAL (CALGB 150007/150012, ACRIN 6657)

Esserman LJ et al. *Proc ASCO* 2009; Abstract LBA515.

## I-SPY TRIAL: pCR in Context of IHC and Select Molecular Subtypes


IHC	pCR (n = 190)	<i>p</i> -value
HR-positive, HER2-negative $(n = 91)$	10%	
HR-positive, HER2-positive $(n = 23)$	32%	NR
HR-negative, HER2-positive ( $n = 23$ )	50%	
HR-negative, HER2-negative (n = $53$ )	33%	>
Gene Profile Intrinsic Subtypes	pCR (n = 144)	<i>p</i> -value
Luminal A or B (n = 72)	17%	
HER2-enriched ( $n = 22$ )	52%	NR
Basal (n = 48)	34%	>

Patients with TNBC are responsive to neoadjuvant paclitaxel/doxorubicin x 4.

Esserman LJ et al. Proc ASCO 2009; Abstract LBA515.

## TNT Trial: A Phase III Trial of Carboplatin versus Docetaxel for Metastatic or Recurrent Locally Advanced TNBC

#### Target accrual = 400 (open)



- Carboplatin = AUC 6 every 3 weeks for six cycles
- Docetaxel = 100 mg/m<sup>2</sup> every 3 weeks for six cycles


www.ClinicalTrials.gov, December 2010.

CALGB-40502/NCCTG N063H: A Phase III Trial of Bevacizumab with Paclitaxel, *Nab* Paclitaxel or Ixabepilone in Patients with Stage IIIC-IV Breast Cancer

#### Target accrual = 900 (open)

#### Eligibility

- Stage IIIC-IV measurable disease ≥ 1 cm by CT scan, or ≥ 2 cm by conventional techniques
- Known ER, PR and HER2 status
- No prior chemotherapy for metastatic disease



## Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer

Baselga J et al. J Clin Oncol 2009;27(4):526-34.

## pCR<sub>Breast</sub> Rates to Neoadjuvant Ixabepilone by Hormone and HER2 Receptor Status

Patient Subgroup	Total Patients	Patients w/ Response	%
All treated patients	161	29	18
ER-negative	72	21	29
ER/PR-negative	61	20	33
ER/PR/HER2-negative	42	11	26

Neoadjuvant ixabepilone is active in various breast cancer subtypes including TNBC

Baselga J et al. J Clin Oncol 2009;27(4):526-34.

Ixabepilone plus Capecitabine vs Capecitabine in Patients with Triple Negative Tumors: A Pooled Analysis of Patients from Two Large Phase III Clinical Studies

Rugo HS et al. *Proc SABCS* 2008;Abstract 3057.

# Capecitabine +/- Ixabepilone: Study Design for CA 163-046 and CA 163-048\*



- Locally advanced or metastatic breast cancer (MBC)
- Pretreated or resistant to taxanes and anthracyclines

**Ixabepilone (Ixa)** 40 mg/m<sup>2</sup> IV over 3 hr d1 q3wk + **Capecitabine** 1,000 mg/m<sup>2</sup> BID 14 days q3wk


**Capecitabine (Cape)** 1,250 mg/m<sup>2</sup> BID 14 days q3wk

\* Phase III trials with similar design. Data pooled (n = 443)

R

Rugo HS et al. Proc SABCS 2008; Abstract 3057.

### **Results: Pooled Analysis of Patients with Metastatic TNBC**



Rugo HS et al. Proc SABCS 2008; Abstract 3057. (Poster) Copyright © 2010, Research To Practice, All rights reserved.

# Conclusions Related to Ixabepilone in Metastatic TNBC

- In the largest clinical data set recorded, Ixa plus Cape in patients with metastatic TNBC resulted in:
  - Prolonged PFS by 2.5 months
  - Doubling of ORR
- Ixa plus Cape did not increase OS compared to Cape alone
- Cape alone offers little benefit for patients with TN MBC previously treated with an anthracycline and a taxane

Rugo HS et al. Proc SABCS 2008; Abstract 3057.

## **TITAN Phase III Trial Design**

#### Target accrual = 1,800 (open)

#### Eligibility

- Histologically confirmed invasive unilateral breast cancer
- Completion of locoregional surgery
- HER2-, PR- and ER-negative

Doxorubicin + Cyclophosphamide  $\rightarrow$  Ixabepilone

Doxorubicin + Cyclophosphamide  $\rightarrow$  Paclitaxel

Doxorubicin = 60 mg/m<sup>2</sup> q21days x 4

R

- Cyclophosphamide = 600 mg/m<sup>2</sup> q21days x 4
- Ixabepilone = 40 mg/m<sup>2</sup> q21days x 4
- Paclitaxel = 80 mg/m<sup>2</sup> weekly x 12

www.ClinicalTrials.gov, December 2010.

### CA163-139 Phase II Trial Design

R

#### Target accrual = 80 (closed)

#### **Eligibility**

- TN locally advanced non-resectable and/or mBC
- No prior systemic therapy

**Ixabepilone** 40 mg/m<sup>2</sup>, 3-week cycle

**Ixabepilone + Cetuximab** Loading dose 400 mg/m<sup>2</sup> then 250 mg/m<sup>2</sup>, weekly

• Study will be completed once all subjects have progressed or 15 months after the Last Patient First Visit, which ever comes first


www.ClinicalTrials.gov, December 2010.

## **BEATRICE** Phase III Trial Design

#### Target accrual = 2,530 (open)

#### Eligibility

- Primary invasive breast cancer
- Centrally confirmed as triple negative
- No clinically significant cardiovascular disease



- **Bevacizumab** = 5 mg/kg/week x 1 year
- Standard chemotherapy = anthracycline with or without taxane or taxane only
- Primary endpoint: DFS

www.ClinicalTrials.gov, December 2010.

Comparison of Subgroup Analyses of PFS from Three Phase III Studies of Bevacizumab in Combination with Chemotherapy in Patients with HER2-Negative Metastatic Breast Cancer

O'Shaughnessy J et al. *Proc SABCS* 2009; Abstract 207. (Poster)

## Improvement in PFS with Addition of Bevacizumab (B) in E2100, AVADO and RIBBON-1

	Improvement in PFS, months (HR)		
Patient Subgroup	E2100 (n = 722)	AVADO* (n = 736)	RIBBON-1 <sup>†</sup> (n = 1,237)
Overall (Hazard Ratio, HR)	5.5 (0.48)	0.8 (0.70); 0.9 (0.61)	2.9 (0.69); 1.2 (0.64)
Triple-negative (HR)	5.3 (0.49)	0.8 (0.69); 2.8 (0.53)	1.9 (0.72); 0.3 (0.78)
Neoadjuvant/adjuvant taxane (HR)	7.3 (0.33)	4.2 (0.62); 1.9 (0.43)	4.5 (0.62); 2.4 (0.65)
Age ≥ 65 (HR)	4.3 (0.67)	0.8 (0.76); 0.8 (0.68)	2.9 (0.69); 1.6 (0.83)

\* B 7.5 mg/kg, 15 mg/kg (doses were also used in the other two trials); † Capecitabine/B; Taxane/anthracycline/B

O'Shaughnessy J et al. *Proc SABCS* 2009; Abstract 207. (Poster)

First-Line Bevacizumab Combination Therapy in Triple-Negative Locally Recurrent (LR)/Metastatic Breast Cancer (mBC): Subpopulation Analysis of Study MO19391 (ATHENA) in >2000 Patients

Thomssen C et al. *Proc SABCS* 2009; Abstract 6093.

## MO19391 (ATHENA) Trial Design

Eligibility (n = 2,251)

HER2-negative No prior chemotherapy or concomitant endocrine therapy

**Bevacizumab + chemotherapy** 

- **Bevacizumab** = 10 mg/kg q2wks or 15 mg/kg q3wks
- Chemotherapy = taxane alone or in combination (clinician's choice) or standard chemotherapy if taxane not considered standard of care

Thomssen C et al. Proc SABCS 2009; Abstract 6093.

# ATHENA Results: Efficacy (median follow-up 12.7 months)

	TNBC (n = 577)	Non-TNBC (n = 1,593)
Median time to progression (TTP)*	7.2 mos	10.4 mos
Overall response rate	47%	53%
Overall survival Deaths, n (%) BC deaths, n (%)	216 (37%) 199 (34%)	398 (25%) 339 (21%)

\* One patient in whom TTP was recorded before treatment start is not included in the TTP analysis.

Thomssen C et al. Proc SABCS 2009; Abstract 6093.

## **Brostallicin – A Novel Cytotoxic Agent**

- Brostallicin is a new synthetic α-bromoacrylic derivative that belongs to the DNA minor groove binding anticancer agents.
- By binding to the DNA minor groove, brostallicin interferes with cell division and leads to apoptosis.
- Active in cancer cells with deficient double-stranded DNA break repair mechanisms and cells with mismatch repair deficiency
- Preclinical and clinical studies indicate that tumors with BRCA1 dysfunction are sensitive to agents that cause DNA damage such as cisplatin and brostallicin.

## N0937: A Phase II Trial of Brostallicin and Cisplatin in Patients with Metastatic Triple-Negative Breast Cancer

#### **Target accrual = 46**

#### **Eligibility**

Metastatic TNBC 0-4 prior therapies for metastatic TNBC Prior cisplatin therapy allowed No uncontrolled CNS metastases

Cisplatin 50 mg/m<sup>2</sup> IV d1 Brostallicin 10 mg/m<sup>2</sup> IV d2 GCSF or pegylated GCSF from d3

- Primary endpoint: PFS at 3 months
- Secondary endpoints: RR, 6-mo PFS, OS, tolerability

www.ClinicalTrials.gov, December 2010.